drugset / Trial / NCT05062837

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

NCT05062837 ↗

NaSingle-groupOpen-labelTreatment

Summary

This study intends to prospectively enroll CNLC stage IIIb HCC cases with extrahepatic metastasis and intrahepatic lesions that are expected to be radical resected in several domestic clinical centers, and observe the OS and ORR, DCR, DOR, TTP and PFS of patients receiving hepatectomy combined with apatinib + carrelli pearl treatment.

Timeline

Start
2021-06-01
Primary completion
2026-12-30
Completion
2026-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody — —
Subject Rivoceranib Small molecule — —